Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.3625
-0.0113 (-3.02%)
Official Closing Price
Updated: 8:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cybin Inc
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright Global Investment Conference
May 11, 2022
Via
Investor Brand Network
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
May 11, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Kernel Share Preliminary Results from Flow Feasibility Study
May 10, 2022
Via
Investor Brand Network
Research Finds That Mushrooms May Have Their Own Language
May 03, 2022
Via
Investor Brand Network
American Billionaire Entrepreneurs Bet Millions on Psychedelics
May 10, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 10, 2022 – Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman...
Via
FinancialNewsMedia
Exposures
Product Safety
U.S. Army Sued Over Discharging Soldiers with Substance-Abuse Issues
May 09, 2022
Via
Investor Brand Network
Topics
Lawsuit
Exposures
Financial
Legal
Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial
May 06, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Preclinical Study Findings to Be Showcased at Global Event Focused on Psychedelic-Assisted Therapy
May 05, 2022
Via
Investor Brand Network
Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine
May 05, 2022
From
Cybin Inc.
Via
Business Wire
Study Says Antidepressants Don’t Meaningfully Improve Depressed People’s Well-Being
May 04, 2022
Via
Investor Brand Network
Vancouver Island University to Expand Psychedelic Mental Healthcare Program
April 29, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Advancing Pipeline in Commitment to Transform Mental Health Treatment Landscape
April 28, 2022
Via
Investor Brand Network
Colorado Patients Reap Benefits of Ketamine Treatments for Depression
April 28, 2022
Via
Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages
April 28, 2022
Via
Investor Brand Network
Oregon to Become the First State to Legally Roll Out Psilocybin
April 28, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in...
Via
FinancialNewsMedia
Topics
Derivatives
ETFs
Exposures
Derivatives
Depression Causes Lasting Physiological Alterations to Immunity Cells
April 26, 2022
Via
Investor Brand Network
Three Kinds of Trauma Psychedelics Hope to Treat
April 25, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at KCSA Psychedelics Virtual Investor Conference
April 22, 2022
Via
Investor Brand Network
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
April 22, 2022
From
Cybin Inc.
Via
Business Wire
Volume of Gray Matter May Be Useful in Treatment Planning for Mental Health Conditions
April 21, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment
April 21, 2022
Via
Investor Brand Network
Roth Capital Reveals Top Psychedelic Picks in New Industry Report
April 21, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report...
Via
FinancialNewsMedia
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
April 21, 2022
From
Cybin Inc.
Via
Business Wire
Cybin (NEO: CYBN) (NYSE American: CYBN) Pipeline Program Receives Key Patent Approval
April 19, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
April 18, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
April 14, 2022
Via
Investor Brand Network
Cybin’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study
April 13, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study
April 13, 2022
Via
Investor Brand Network
Why Psychedelics Could Soon Replace Antidepressants
April 13, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults...
Via
FinancialNewsMedia
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
April 13, 2022
From
Cybin Inc.
Via
Business Wire
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.